Navigation Links
Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
Date:5/10/2010

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

In patients with type 1 diabetes, T cells of the immune system attack and destroy beta cells that are located in the pancreas and make insulin. Teplizumab works by binding to CD3 receptors on the surface of the T cells and, by doing so, may modulate the autoimmune attack on pancreatic beta cells and preserve or protect these cells. If effective, patients may require less injected insulin and their blood glucose levels may be easier to control.

In an earlier trial of teplizumab, a small group of subjects with diabetes of recent onset were noted to have improved function of their beta cells, improved glucose control, and reduced insulin requirements for up to two years. These findings are being further studied in the Protege and Protege Encore clinical trials.

The Protege Encore trial is designed to determine if teplizumab can preserve pancreatic insulin production, which may make diabetes easier to manage. "We have a lot of enthusiasm about the teplizumab studies and their implications. It is hoped that one day we can offer a new treatment option to help patients better manage their disease," Dr. Hays commented.

Approximately 125 study sites across 16 countries will be enrolling 400 individuals who have been to a physician with signs and symptoms of type 1 diabetes within the past 12 weeks. Most study sites are enrolling individuals 8–35 years old, and Dr. Hays is enrolling individuals 8–17 years old. Subjects will receive one of three study treatment regimens, or placebo. Subjects will be followed over a 2-year period.

Additional information on Protege Encore and all participating study sites is available at www.protegediabetes.org/news.  Dr. Hays can also be reached directly at 561-641-7736.

About Dr. Richard Hays

Richard M. Hays, M.D., P.A., completed his undergraduate education at Johns Hopkins University in Baltimore, his M.D., at the University of Florida College of Medicine in Gainesville, and his residency at the Duke-Watts Family Medicine Residency Program in Durham, N.C. He is board certified in family medicine and is a fellow of the American Academy of Family Physicians (AAFP). Dr Hays has been in private practice since 1989, with staff privileges at Wellington Regional Medical Center in Florida, where he is chief of the Department of Family Practice. Dr. Hays is a member of several professional societies, including AAFP and the Florida Academy of Family Physicians. He is also certified by the National Committee on Quality Assurance for special qualification in care of patients with diabetes.


'/>"/>
SOURCE Richard M. Hays, M.D., P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
9. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
10. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... India , May 20, 2016 ... - Pipeline Review, H1 2016" market research report ... Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance ... summit on September 15 and 16, 2016 in San Diego, CA. The two ... bearers will be one of the largest gatherings of medical device companies, suppliers, professionals ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... 23, 2016 , ... Octo Consulting Group, a leading provider of innovative information ... announce they have recently won two awards from AFCEA International. Octo was selected ... Year. Additionally, Octo VP of Civilian Affairs, Naina Leo, was named a winner of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
Breaking Medicine News(10 mins):